STOCK TITAN
  1. Home
  2. Sec-filings
  3. TWST
  4. [Form 4] Twist Bioscience Corporation Insider Trading Activity

Twist Bioscience (TWST) Form 4: Sell-to-cover of 521 shares reported

Filing Impact
(Neutral)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Dennis Cho, Senior Vice President, Chief Legal Officer & Corporate Secretary of Twist Bioscience Corporation (TWST), reported a sale of 521 shares of TWST common stock on 08/21/2025 at a price of $25.964 per share. The Form 4 notes the sale was a "sell to cover" transaction required to satisfy tax withholding upon vesting of Restricted Stock Units and not a discretionary trade. After the transaction the reporting person beneficially owned 103,306 shares directly. The form was signed by an attorney-in-fact, Kendra Fox, on 08/25/2025.

Positive

  • Transparent disclosure of a tax-related "sell to cover" rather than an unexplained sale
  • Reporting person retains substantial direct ownership of 103,306 shares after the transaction
  • Form filed and signed (via attorney-in-fact), meeting Section 16 reporting requirements

Negative

  • None.

Insights

TL;DR: Insider sold a small number of shares to cover taxes after RSU vesting; not a signal of voluntary disposition.

The filing documents a routine "sell to cover" of 521 shares at $25.964, explicitly to satisfy tax withholding from RSU vesting. This type of transaction is administrative and typically lacks informational content about management's view of the company. The remaining direct beneficial ownership of 103,306 shares keeps the reporting person's stake intact. No derivative transactions or additional disposals are reported.

TL;DR: Disclosure is compliant and transparent, showing required tax-related disposition rather than opportunistic selling.

The Form 4 includes the required explanation that the sale was mandated by the issuer's election under its equity plans to perform a sell-to-cover for tax withholding. Filing was executed via attorney-in-fact, which is common. The report lists direct ownership and does not indicate change in officer status. From a governance perspective, the form meets disclosure obligations and contains no material adverse signals.

Insider Cho Dennis
Role See Remarks
Sold 521 shs ($14K)
Type Security Shares Price Value
Sale Common Stock 521 $25.964 $14K
Holdings After Transaction: Common Stock — 103,306 shares (Direct)
Footnotes (1)
  1. [object Object]
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Cho Dennis
(Last) (First) (Middle)
C/O TWIST BIOSCIENCE CORPORATION
681 GATEWAY BLVD
(Street)
SOUTH SAN FRANCISCO CA 94080
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Twist Bioscience Corp [ TWST ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
See Remarks
3. Date of Earliest Transaction (Month/Day/Year)
08/21/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 08/21/2025 S 521(1) D $25.964 103,306 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.
Remarks:
Senior Vice President, Chief Legal Officer & Corporate Secretary
/s/ Kendra Fox, as Attorney-in-Fact for Dennis Cho 08/25/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What did Dennis Cho report on Form 4 for TWST?

The Form 4 reports a sale of 521 shares of TWST common stock on 08/21/2025 at $25.964 per share to satisfy tax withholding from RSU vesting.

Was the sale by the reporting person discretionary?

No. The filing states the sale was a "sell to cover" mandated by the issuer's election under its equity incentive plans to satisfy tax withholding obligations.

How many TWST shares does Dennis Cho own after the reported transaction?

After the reported transaction the reporting person beneficially owned 103,306 shares directly.

What is Dennis Cho's role at Twist Bioscience (TWST)?

The Form 4 identifies Dennis Cho as Senior Vice President, Chief Legal Officer & Corporate Secretary.

When was the Form 4 signed and by whom?

The filing was signed by Kendra Fox as attorney-in-fact for Dennis Cho on 08/25/2025.